Metal Ion Homeostasis In Alzheimer'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Transition metals are essential for normal brain function:
- Iron: Oxygen transport, mitochondrial function, neurotransmitter synthesis
- Copper: Enzyme cofactor for cytochrome c oxidase, SOD, dopamine β-hydroxylase
- Zinc: Synaptic signaling, enzyme cofactor, DNA binding
In AD, metal homeostasis is disrupted, leading to:
- Accumulation in amyloid plaques
- Increased oxidative stress
- Altered amyloid processing
- Synaptic dysfunction
Iron is the most abundant metal in the brain:
- Ferritin levels increase in AD neurons
- Iron accumulates in amyloid plaques
- DMT1 expression is altered
- Contributes to oxidative damage
The study of Metal Ion Homeostasis In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
- PMID:16489445 - Iron in AD pathogenesis
- PMID:18818082 - Brain iron metabolism in AD
- PMID:22510191 - Iron and neurodegeneration
Copper plays roles in multiple enzymatic reactions:
- Ceruloplasmin levels are altered in AD
- Aβ binds copper with high affinity
- Copper accelerates Aβ aggregation
- Cytochrome c oxidase activity decreases
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
- PMID:15728264 - Copper and AD
- PMID:18436543 - Copper homeostasis in brain
- PMID:21793638 - Copper in amyloidogenesis
Zinc is crucial for synaptic transmission:
- Zinc accumulates in amyloid plaques
- Aβ-zinc interactions promote aggregation
- Synaptic zinc signaling is disrupted
- Zinc transporters are dysregulated
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
- PMID:16876757 - Zinc in AD
- PMID:18796312 - Zinc and amyloid beta
- PMID:22572647 - Zinc transporters in neurodegeneration
Fenton chemistry generates reactive oxygen species:
- Iron and copper catalyze ROS formation
- 4-HNE and 8-OHdG increase in AD
- Antioxidant defenses are overwhelmed
- Lipid peroxidation damages membranes
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
- PMID:16219934 - Metal-induced oxidative stress in AD
- PMID:19666078 - Fenton chemistry in neurodegeneration
Aβ has high affinity for metal ions:
- Cu²⁺ and Zn²⁺ bind to Aβ
- Metal-Aβ complexes are neurotoxic
- Accelerates plaque formation
- Alters Aβ aggregation pathway
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
- PMID:10955575 - Metal-Aβ interactions
- PMID:14501118 - Copper and Aβ aggregation
Metal homeostasis is a potential therapeutic target:
- Chelators: Deferoxamine, clioquinol
- Metal-protein attenuating compounds (MPACs)
- Antioxidants: CoQ10, vitamin E
- Metal homeostasis modulators
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
- PMID:15837641 - Clioquinol in AD clinical trial
- PMID:23415645 - Metal chelation therapy in AD
flowchart TD
A[Iron Accumulation] --> B[Fenton Reaction] -->
A --> C[Ferritin Increase] -->
B --> D[ROS Generation] -->
C --> E[Protein Aggregation)
F[Copper Dysregulation] --> G[Cytochrome C Oxidase Decrease] -->
F --> H[Aβ-Copper Complexes] -->
G --> I[Mitochondrial Dysfunction)
H --> E
D --> J[Oxidative Stress)
I --> J
E --> K[Amyloid Plaque Formation] -->
J --> L[Lipid Peroxidation] -->
L --> M[Neuronal Death] -->
K --> N[Synaptic Dysfunction)
N --> M
M --> O[Cognitive Decline] -->
P[Zinc Dysregulation] --> Q[Synaptic Zinc Signaling Disruption] -->
P --> R[Aβ-Zinc Aggregation] -->
Q --> N
R --> K
- Serum ferritin as AD biomarker
- Ceruloplasmin/ferritin ratio
- CSF metal levels
- Chelation therapy: Controversial results
- Clioquinol: Early trials showed promise
- PBT2: Phase II trials
- Natural chelators: Green tea polyphenols
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
- PMID:21820744 - Metal homeostasis as biomarker
- PMID:25256382 - PBT2 in AD
- PMID:28750524 - Copper chelation in neurodegenerative disease
Metal ion dysregulation is both a cause and consequence of AD pathogenesis. Metal-Aβ interactions promote aggregation, while metal-induced oxidative stress accelerates neuronal damage. Restoring metal homeostasis remains a therapeutic challenge but offers disease-modifying potential.
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
- Thompson KJ, Oruna R, Connor JR, Iron and Alzheimer's disease, Frontiers in Aging Neuroscience, 2011
- Cai Z, Wang C, He W, Iron dysregulation in Alzheimer's disease, Journal of Alzheimer's Disease, 2014
- Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L, The role of iron in brain ageing and neurodegenerative disorders, Lancet Neurology, 2014
- Squitti R, Ghidoni R, Scrascia E, Benussi L, Panetta V, Pasqualetti P, Liberati B, Miraglia E, Alieri G, Lutjohann D, Lupton M, Rossini PM, Copper dysregulation in Alzheimer's disease, Journal of Alzheimer's Disease, 2011
- Vassallo N, Edelstyn NM, Copper and zinc in Alzheimer's disease, Journal of Alzheimer's Disease, 2011
- Hung YH, Bush AI, La Fontaine S, Links between copper and cholesterol in Alzheimer's disease, Frontiers in Aging Neuroscience, 2013
- Sensi SL, Granzotto A, Siotto M, Squitti R, Copper and zinc dysregulation in Alzheimer's disease, Advances in Neurobiology, 2017
- Crouch PJ, Hung LW, Adlard PA, Corr M, Talbot ML, Crane LI, State transition metal dyshomeostasis and the pathogenesis of Alzheimer's disease, Behavioural Brain Research, 2009
- Rott R, Fortgang R, Kotovich M, Ziv N, M factor and the role of zinc in Alzheimer's disease, Neurobiology of Aging, 2009
- Lee JY, Mook-Edltz FJ, Koh JY, Elevation of zinc levels in the brains of patients with Alzheimer's disease, Journal of Neurology, 2009
- Zhang LH, Wang X, Stoltenberg M, Danscher G, Jensen AA, Zinc transporter ZnT3 and zinc homeostasis in brain, Progress in Neurobiology, 2008
- Gaggelli E, Kozlowski H, Valensin D, Valensin G, Copper homeostasis and neurodegenerative disorders, Chemical Reviews, 2006
- Bush AI, Drug development for Alzheimer's disease: where are we now and where are we heading?, Annals of Neurology, 2012
- Roh E, Park DK, Choi BO, Kim YH, Kim BJ, Serum ceruloplasmin as a prognostic factor in Korean patients with Alzheimer's disease, Journal of Clinical Neurology, 2012
- Kaur D, Andersen J, Does iron dysregulation play a causative role in Parkinson's disease?, Ageing Research Reviews, 2004
- Bonda DJ, Lee HG, Blair JA, Zhu X, Perry G, Smith MA, Role of metal chelation in the pathogenesis of Alzheimer's disease, International Journal of Alzheimer's Disease, 2011
- Lannfelt L, Blennow K, Zetterberg H, Batsman K, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Efficacy and safety of the copper-mediated compound PBT2 in patients with mild-to-moderate Alzheimer's disease, The Lancet Neurology, 2008
- Dexter DT, Jenner P, Schapira AH, Marsden CD, Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia, Annals of Neurology, 1992
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
3 references |
| Replication |
100% |
| Effect Sizes |
50% |
| Contradicting Evidence |
100% |
| Mechanistic Completeness |
50% |
Overall Confidence: 56%